Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer

Samsung Medical Center1,000 enrolled

Overview

To prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. The specimens will be analyzed using DNA/RNA/proteomic approaches.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Sarcoma

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer 2. Written informed consent 3. body fluid derived from cancer, available for drainage and collection Exclusion Criteria: * patients who do not give informed consent form for research use of biomaterials/biospecimens

Locations (1)

Samsung Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Biomarker analyses to predict treatment response in metastatic cancer

Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.

Time frame: 3 year

Central Contacts

Jeeyun Lee, MD

CONTACT

822-3410-3459 jyun.lee@samsung.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.